The extension granted by Nasdaq allows Eloxx Pharmaceuticals more time to regain compliance with the market value of listed securities requirement. This could potentially alleviate some of the pressure on the company and may be seen as a positive sign by investors, possibly leading to a short-term increase in the stock price.